Remitly Global Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Remitly Global Inc trades at $23.5 (market cap $4.85B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 5.2× Remitly Global Inc's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (5,738,571 versus 2,599,081). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| RELY | ROIV | |
|---|---|---|
Market Cap | $4.85B | $25.09B |
Volume | 2,599,081 | 5,738,571 |
Sector | Technology | Health |
52-Week High | $26.92 | $41.81 |
52-Week Low | $12.20 | $16.04 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $4.22B | $21.36B |
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.52, up 1.38% today, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and turning profitable with a net income of $67.93M. Recent Q2 2026 earnings beat expectations with EPS of $0.93 versus $0.12 expected, and active customers surpassed 10 million. Positive cash flow trends and a partnership with Etsy highlight operational strength and growth initiatives.
The outlook for RELY is positive, supported by accelerating revenue growth, expanding profit margins, and strong analyst consensus with a $30.50 price target. Key risks include reliance on continued customer expansion, competitive pressures in digital payments, and market volatility. The stock presents an opportunity for growth investors given its earnings beats and bullish institutional sentiment, though execution on growth targets remains critical.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →